Custome No. 28880

HON 5 5 5000

Sheet

Confirmation No. 7109

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Co	mplete if Known	
Application Number	10/634,180	
Filing Date	August 5, 2003	
First Named Inventor	Bunker, et al	
Art Unit	1624	
Examiner Name	Deepak R. Rao	
Attorney Docket Number	PC25245A	

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (F known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
VOR		US- 2003/0078276	04-24-2003	Andrianjara, et al	
MAR		US- 2002/0193377	12-19-2002	Andrianjara, et al	
WR		US- 2003/0144274 ·	07-31-2003	Bunker, et al	
WR		US- 6,008,243	12-28-1999	Bender, et al	
NOR		US- 2002/086890	07-04-2002	Levin, et al	
		US-	· ·		
		US-			
		US-			
		US-			,
		US-			
		US-			
	l	US-			
•		US-			
		US-			
	 	US-			
		US-			
		US-			
	<u> </u>	US-			
	\vdash	US-			

		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.
_		Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T*
LER		WO 02/064080	08-22-2002	Andrianjara, et al		
WK		WO 02/064572	08-22-2002	Andrianjara, et al		
00K		WO 03/032999	04-24-2003	Bunker, et al		
OUR		WO 01/63244	08-30-2001	Chen, et al		
WX		WO 00/09485	02-24-2000	McClure, et al		
00/2		WO 01/12611	02-22-2001	Blagg		

Examiner Signature	VII	neck less	Date Considered	3/20/05

*EXAMINER: Initial if reference considered, whether or not citation if in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031

	Under	the Paperwork Reduc	tion Act of 1995, r	o persons are required t	U.S. Patent and Trader o respond to a collection of informa	mark Office; U.S. DEPARTMENT Of tion unless it contains a valid OMB of	F COMMERCE control number.		
		titute for form 1449/P			Complete if Known				
	3003	alberto to to to to			Application Number	10/634,180			
	18.1	CODIATI	ON DICC	OCUBE	Filing Date	August 5, 2003			
INFORMATION DISCLOSURE		First Named Inventor	Bunker, et al						
	SI	TATEMEN	T BY API	PLICANT	Art Unit	1624			
		(Use as man	y sheets as nece	ssary)	Examiner Name	Deepak R. Rao			
	Shoot	2	of	4	Attorney Docket Number	PC25245A			

			U. S. PATENT D		Pages, Columns, Lines, Where
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (f Incurt)}			rigures repeat
		US-		. <u> </u>	
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
	†	US-			
	 	US-			
	t	US-			

		FORE	IGN PATENT DOCI	JMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.
_		Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	To
WR		WO 02/34726	05-02-2002	Noe, et al		
1		WO 02/34753	05-02-2002	Bronk, et al		
		EP 0935963	08-18-1999	McClure, et al		L
		EP 1138680	10-04-2001	Noe		
		WO 99/64400	12-16-1999	Salituro, et al		L
V		EP 1069110 A	01-17-2001	Kimura, et al		

					_
Examiner Signature	Dunak Clerch	Date Considered	3	20/05	` _

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation if right in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Nind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Rao, Deepak R.

PC25245A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid QMB control number.

Substitute for form 1449/PTO

Application Number 10/634,180

Filing Date August 5, 2003

First Named Inventor Bunker, et al

Art Unit 1624

Attorney Docket Number

Examiner Name

(Use as many sheets as necessary)

of

4

Sheet

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
-		International Search Report from PCT/IB 03/03508.	
10k		Billinghurst, et al. "Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase", Arthritis & Rheumatism, March 2000, vol. 43, No. 3, pp. 664-672.	
·		Office Action from 10/264,764 mailed 6.16.03.	
ØR.		Moy, et al. "High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor", J. mol. Biol., (2000), 302, pp. 671-689.	
10g		Lovejoy, et al, "Crystal Structures of MMP-1 and -13 reveal the Structural Basis for Selectivity of Collagenase Inhibitors", Nature Structural Biology, Vol. 6, No. 3, March 1999, pp. 217-221.	
WR		Billinghurst, et al, "Enganced Cleavage of Type II Collagen by Collagenasees in Osteoarthritic Articular Cartliage", J. Clin. Invest., April 1997, Vol. 99, No. 7, pp. 1534-1545.	
WR		Chen, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, Vol. 122, pp. 9648-9654.	
WR		Wernicke, et al, "Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis", The Journal of Rheumatology, 1996, Vol. 23, No. 4, pp.590-595.	
WK		Mokrosz, et al, "Structure-activity relationship studies of CNS agents Part 10: 1-Aryl-2-[3-(4-aryl-1-piperazinyl)propyl]-1,4-dihydro-3(2 H)-isoquinalones: Two modes of the interaction with the 5-HT receptor site", Pharmazie, 1994, Vol. 49, pp. 328-333.	
NOR		Reboul, et al "The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes", J. Clin. Invest., Vol. 97, No. 9, May 1996 pp.2011-2019.	

Examiner Signature Date Considered \$\frac{20}{0.5}\$

^{*}EXAMINER: tritial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
redemark Office: U.S. DEPARTMENT OF COMMERCE

Rao, Deepak R.

PC25245A

Under the Paperwork Reduction Act of 1995, no persons as		on of Information unless it contains a valid OMB control number	
ubstitute for form 1449/PTO		Complete if Known	١
	Application Number	10/634,180	
NFORMATION DISCLOSURE	Filing Date	August 5, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Bunker, et al	
	Art Unit	1624	7

Attorney Docket Number

Examiner Name

(Use as many sheets as necessary)

of

4

Sheet

Examiner

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T²
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1-
W _R		Neuhold, et al, "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice", J. Clin. Invest., January 2001, Vol. 107, No. 1, pp. 35-44.	
W.		Mitchell, et al, "Cloning Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage", J. Clin. Invest., February 1996, Vol. 97, No. 3, pp. 761-768.	
WR		Dahlberg, et al, "Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor That Spares Collagenase I (Matrix Metalloproteinase I)", Arthritis & Rheumatism, March 2000, Vol. 43, No. 3, pp. 673-682.	
10R		Freemont, et al, "In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage", Ann. Rheum. Dis., 1999, Vol. 58, pp. 357-365.	
<u> </u>			
	-		
-			

20 Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Date

considered. Include copy of this form with next communication to applicants.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.